Peptides for inhibiting chemokine binding to chemokine receptors

{
  "publication_number": "US8039440B2",
  "country": "US",
  "kind": "B2",
  "title": "Peptides for inhibiting chemokine binding to chemokine receptors",
  "abstract": "Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.",
  "claims": [
    "1. An isolated peptide chemokine modulator comprising a peptide comprising the amino acid sequence of SEQ ID NO: 101.",
    "2. A composition comprising the peptidic chemokine modulator of claim 1, the composition being for inhibiting a binding of a chemokine to a chemokine receptor, wherein said chemokine is selected from the group consisting of MCP-1 (monocyte chemotactic protein-1), MIG (monokine induced by gamma interferon), Eotaxin and IL-8.",
    "3. The composition of claim 2, further comprising a pharmaceutically acceptable carrier.",
    "4. The composition of claim 3, wherein said carrier is for topical administration.",
    "5. The composition of claim 3, wherein said pharmaceutically acceptable carrier is for inhalation.",
    "6. The composition of claim 3, wherein said pharmaceutically acceptable carrier is for intranasal administration.",
    "7. The composition of claim 3, wherein said pharmaceutically acceptable carrier is for systemic administration.",
    "8. An isolated peptide chemokine modulator comprising a peptide comprising the amino acid sequence of SEQ ID NO: 64.",
    "9. A composition comprising the peptide chemokine modulator of claim 8, the composition being capable of inhibiting a binding of a chemokine to a chemokine receptor, wherein said chemokine is selected from the group consisting of MIG (monokine induced by gamma interferon) and IL-8.",
    "10. The composition of claim 9, further comprising a pharmaceutically acceptable carrier.",
    "11. The composition of claim 10, wherein said carrier is for topical administration.",
    "12. The composition of claim 10, wherein said pharmaceutically acceptable carrier is for inhalation.",
    "13. The composition of claim 10, wherein said pharmaceutically acceptable carrier is for intranasal administration.",
    "14. The composition of claim 10, wherein said pharmaceutically acceptable carrier is for systemic administration.",
    "15. An isolated peptide chemokine modulator comprising a peptide comprising the amino acid sequence of SEQ ID NO: 76.",
    "16. A composition comprising the peptide chemokine modulator of claim 15, the composition being capable of inhibiting a binding of a chemokine to a chemokine receptor, wherein said chemokine is selected from the group consisting of MCP-1 (monocyte chemotactic protein-1) and MIG (monokine induced by gamma interferon).",
    "17. The composition of claim 16, further comprising a pharmaceutically acceptable carrier.",
    "18. The composition of claim 17, wherein said carrier is for topical administration.",
    "19. The composition of claim 17, wherein said pharmaceutically acceptable carrier is for inhalation.",
    "20. The composition of claim 17, wherein said pharmaceutically acceptable carrier is for intranasal administration.",
    "21. The composition of claim 17, wherein said pharmaceutically acceptable carrier is for systemic administration."
  ],
  "description_excerpt": "The present invention discloses novel peptidic molecules or peptidomimetic agents, which are capable of binding chemokines and modulating their biological functions.\n\nDrug discovery in the post-genomics era provides enormous opportunities as well as new challenges. The targets of the drug discovery process have changed greatly over the last 50 years. The development of advanced purification technologies and the tools of molecular biology have brought molecular targets into the current discovery process. In the last ten years, there has been a trend towards selecting molecular targets for the screening process, and the human and other genome projects have made available many thousands of additional targets for drug discovery.\n\nIn addition to these novel targets with unknown potential, there are a significant number of well-validated targets associated with major human diseases. Most of these are either nuclear receptors or G protein-coupled receptors. It was found, that in some cases, one compound that has an effect through one receptor, can also act through another receptor, and that several compounds can work through the same receptor. Unfortunately, even when the mechanism of a disease process is understood, for example by identifying the receptor(s) responsible for such a process, this information has not always resulted in the development of new treatments. For example, subjects who suffer from inflammation associated diseases and disorders have a great and desperate demand for novel drugs as therapeutic agents. Current therapies are merely palliative and have not been significantly improved in recent years.",
  "cpc": [
    "A61K 38/10",
    "A61K 38/00",
    "A61K 38/08",
    "A61K 39/00",
    "A61P 17/06",
    "A61P 19/02",
    "A61P 29/00",
    "A61P 3/10",
    "A61P 31/04",
    "A61P 31/12",
    "A61P 35/00",
    "A61P 37/06",
    "A61P 37/08",
    "A61P 9/10",
    "A61P 9/12",
    "B65G 11/023",
    "B65G 11/163",
    "C07K 7/08",
    "C07K 7/64"
  ],
  "ipc": [
    "A61K 38/00",
    "A61K 38/08",
    "A61K 38/10",
    "A61K 39/00",
    "B65G 11/02",
    "B65G 11/12",
    "B65G 11/16",
    "C07K 7/08",
    "C07K 7/64"
  ],
  "assignees": [
    "Biokine Therapeutics Ltd"
  ],
  "inventors": [
    "Amnon Peled",
    "Orly Eizenberg",
    "Dalit Vaizel-Ohayon"
  ],
  "filing_date": "2009-01-22",
  "publication_date": "2011-10-18",
  "grant_date": "2011-10-18",
  "priority_date": "2002-02-28",
  "application_number": "US-32028109-A",
  "family_id": "27766173",
  "cited_by_count": 2,
  "citations": [
    "US5840693A",
    "WO2002061087A2",
    "US20030027751A1",
    "US20030166004A1",
    "WO2003072599A2",
    "US20040171552A1"
  ]
}